# Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults

> **NCT06125691** · PHASE1 · COMPLETED · sponsor: **Arcturus Therapeutics, Inc.** · enrollment: 139 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** ARCT-2138
- **BIOLOGICAL:** Licensed Quadrivalent Vaccine for younger adults
- **BIOLOGICAL:** Licensed Quadrivalent Vaccine for older adults

## Key facts

- **NCT ID:** NCT06125691
- **Lead sponsor:** Arcturus Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-22
- **Primary completion:** 2024-08-10
- **Final completion:** 2025-01-07
- **Target enrollment:** 139 (ACTUAL)
- **Last updated:** 2025-10-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06125691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06125691, "Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06125691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*